Integrase Inhibitors
6,776 views
Antivirals
- Oseltamivir, Zanamivir
- Acyclovir (Famciclovir, Valacyclovir)
- Ganciclovir
- Foscarnet
- Cidofovir
- NRTIs
- NNRTIs
- Integrase Inhibitors
- Protease Inhibitors
- Entry Inhibitors (Enfuvirtide, Maraviroc)
- NS5A Inhibitors
- NS5B Inhibitors
- NS3/4A Inhibitors
Summary
Integrase inhibitors are drugs that end in the suffix “-tegravir”, including Raltegravir and Dolutegravir. As the name integrase inhibitor suggests, these drugs inhibit the enzyme integrase found in HIV, blocking the integration or insertion of newly-synthesized viral DNA into the host cell. Integrase inhibitors are active against both subtypes of HIV, and are commonly administered as a component of the HAART combination regimen, or Highly Active Antiretroviral Therapy. However, one potential side effect of integrase inhibitors is muscle damage that often presents as myositis.
Key Points
- Integrase Inhibitors
- Drug Names (-tegravir ending)
- Raltegravir
- Dolutegravir
- Bictegravir
- Elvitegravir
- Mechanism
- Inhibit retroviral integrase
- Blocks integration of HIV viral DNA (made by reverse transcriptase) into host cell chromosome
- Prevents viral usage of host machinery for replication
- Inhibit retroviral integrase
- Indications
- HIV
- Active against both HIV-1 and HIV-2
- Component of highly-active antiretroviral therapy (HAART)
- Usually 3 drugs: 2 NRTIs and integrase or protease inhibitor
- HIV
- Adverse Effects
- Myositis (myopathy)
- Increase creatine kinase levels
- Myositis (myopathy)
- Drug Names (-tegravir ending)